Medical management of benign prostatic hyperplasia: A review

East African Medical Journal

Volumn 73, Issue 7, 1996, Pages 453-456

  Magoha, G A O ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO ACID; ANDROSTANOLONE; DOXAZOSIN; EPISTERIDE; FINASTERIDE; INDORAMIN; KAMPO; PHENOXYBENZAMINE; PLANT EXTRACT; PRAZOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

HUMAN; HYPERPLASIA; HYPOTENSION; MALE; PHYTOTHERAPY; PROSTATE; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 0030431269     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Berry, S.J., Coffey, D.S., Walsh, P.C. and Ewing, L.L. The development of benign prostatic byperplasia with age. J. Urol. 1984; 132:474-479.
2. Garraway, W.M., Collis, G.N, and Lee, R.J. High prevalence of benign prostate hypertrophy in the community. Lancet. 1991; 338:469-471
3. Mckelvie, G.B., Collins, G.N., Hehir, M. and Rogers, A.C.N. A study of benign prostatic hyperplasia A challenge to British Urology. Brit. J. Urol. 1993; 71:38-42.
4. Mebust, W.K., Holtgrave, H.L. and Cockett, A.T.K. Transurethral prostatectomy. Immediate and post operative complications. Acooperative study of 13 participating Institutions evaluating 3855 patients.J. Urol. 1989; 141:243-247.
5. Chilton, C.P. Morgan, R.J. and England, H.R. et al. A critical evaluation of results of transurethral resection of the prostate. Brit. J. Urol. 1978; 50:542-546.
6. Roos, N.P., Wemberg, I.C. and Malenka, D.J. et al. Mortality and re-operation after transurethral resection of the prostate for benign prostatic hyperplasia. N. Engl. J. Med. 1989; 320:1120-1124.
7. Hargreave, T.B., Heynes, C.F., Kandrick, B., White, B. and Clarke, J.A. Mortality after transurethral and open prostatectomy in Scotland. Brit. J. Urol. 1996; 77:547-553.
8. Caine, M. Reflections on alpha blockade therapy for benign prostatic hyperplasia. Brit. J. Urol. 1995; 75:265-270.
9. Keoghane, S.R., Cranston, D.W., Lawrence, K.C., Doll, H.A., Fellows, G.J. and Smith, J. C. The oxford laser prostate trial. A randomised controlled trial of contact vaporization of the prostate versus TURP. J. Urol. 1995; 5:230 (abst).
10. Venn, S.N., Montgomery, B.S.I. Sheppard, S.A., Hughes, S.W., Beard, R.C., Bultitude, M.I., Llyoid-Davies, R.W. and Tiptaft, R.C. Microwave hyperthermia in benign prostatic hypertrophy, A controlled trial. Brit. J. Urol. 1995; 76:73-76.
11. Donatucci, C.F., Berger, N., Kreder, K.J., Donohue, R.E., Raide, M.J. and Crawford, E.D. Randomised clinical trial comparing baloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. Urology. 1993; 42:42-49.
12. Williams, G., Coulance, C., Milroy, E.J.G., Darraman, J.P. and Rubben, H. Urolume a permanently implanted prostatic stent for patients at high risk of surgery. Results from five collaborative centres. Brit. J. Urol. 1993; 72:335-340.
13. Zlotta, A.R., Peny, M.O., Matos, C. and Schulman, C.C. Transurethral needle ablation of the prostate Clinical experience in patients in acute urinary retention. Brit. J. Urol. 1996; 77:391-397.
14. Walsh, P.C. Benign prostatic hyperplasia in campbells Urology, Vol. 1 WB Saunders 1992; 6:1009-1027.
15. Kawabe, K. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Brit. J. Urol. 1995;76(Supp 1):63-67.
16. Bosch, R.J.L.H, Griffiths, D.J, Blom, J.H.M. and Schroeder, F.H. Treatment of benign prostatic hyperplasia by androgen deprivation. Effects on prostate size and urodynamic parameters. J. Urol. 1989; 141:68-72.
17. Geller, J., Bora, R., Robberts, T., Newman, H., Lin, A. and Silva, R. Treatment of benign prostatic hypertrophy with hydroxyprogesteronecaproate. Effect on clinical symptoms, morhology and endocrine function. J. Amer. Med. Ass. 1965:193-121
18. Stone, N.N. Flutamide in the treatment of benign prostatic hypertrophy. Urology. 1989; 39:64
19. Stoner, E. The clinical development of a 5 alpha reductase inhibitor, finasteride. J. Steriod. biochem. 1990; 37:375-378.
20. Caine, M., Pfau, A. and Perlberg, S. The use of alpha -adrenergic blockers in benign prostatic obstruction. Brit. J. Urol. 1976; 48:255-263
21. Lepor, H. and Shapiro, E. This month in investigative urology. Alpha adrenergic innervation of the prostate. Insights into the pharmacology of benign prostatic hyperplasia. J. Urol. 1990; 143:590
22. Wilson, J.D. The in tranucear metabolism of testosterone in the accessory organs of reproduction. Recent. Prog. Horm. Res. 1970; 26:309-336.
23. Siiteri, P. K. and Wilson, J.D. Testosterone formation and metabolism during male sexual differentiation in the human embryo. J. Clin. Endocrinol. metab. 1974; 38:113
24. Brooks, J.R., Berman, C., Glitzer, M.S., Gordon, L.R., Primkac, R.L., Reynolds, G.F. and Rasmusson, G.H. The effect of a new 5-alpha reductase inhibitor on the size, histological characteristics and androgen concentration of canine prostate. Prostate. 1982; 3:35
25. McConnel, J.D., Wilson, J.D., George, F.W., Geller, J., Walsh, P.C., Ewinwg, L.L., Isaacs, J. and Stoner, E. An inhibitor of 5 alpha reductase, mk 906 suppresses prostatic Dihydrotestosterone in men with benign prostatic hyperplasia. J. Urol. 1989; 141:299A
26. Gormley, G.J., Stoner, E. and Bruskewitz, R.C. et al The effectof finasteride in men with benignprostatichyperplasia. N. Engl. J. Med 1992; 327:1185-1191.
27. Stoner, E. and members of finasteride study group. Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994; 43: 284-294.
28. Guess, H. A. Effect of finasteride on serum PSA concentrations in men with benign prostatic hyperplasia. Results from the North American phase 111 clinical trial. Urol. Clin. N. Amer. 1993; 20: 627-636.
29. Caine, M. The present role of alpha-adrenergic Blockers in the treatment of benign prostatic hypertrophy. J. Urol. 1986; 136: 1-4
30. Chapple, C.R., Aubry, M.L. and James, S. et al. Characterisation of human prostatic Adrenoceptors using pharmacology receptor Binding and Localisation. Brit. J. Urol. 1989; 63: 487-496.
31. Lepor, H. Alpha -1- adrenoceptor selectivity. Clinical or theoretical benefit. Brit. J. Urol. 1995; 76 suppl 1: 57-61.
32. Lepor, H. Non operative management of benign prostatic hypertrophy. J. Urol. 1989; 141:1283-1289.
33. Minneman, K.P., Han, C. and Abel, P.W. Comparison of alpha one adrenergic receptor subtypes distinguished by chlorethyl-clonidine and WB 4101. Mol. Pharmacol. 1988; 33:509-514.
34. Schwinn, D.A. Lomasney, J.W. and Lorenz, W. et al. Molecular cloning and expression of c-DNA for a novel alpha 1-adrenergic receptor subtype. J. Biol. Chem. 1990; 265:8183-8189.
35. Lepor, H. Tang, R. and Shpiro, E. The alpha adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate. 1993; 22:301-307.
36. Forray, C., Barf, J.A. and Wetzel, J.M. et al. The alpha adrenergic receptor that mediates Smooth muscle contraction in human prostate Has the pharmacological properties of the cloned human alpha 1C subtype. Mol. Pharmacol. 1994; 45:703-708.
37. Reuther, K. and Aagaard, J. Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers. Urol. Int. 1984; 39:114-115.
38. Uson, A.C. Paez, A.B. and Uson-Jaeger, J. The natural history and course of untreated Benign prostatic hyperplasia. Eur. Urol. 1991; 20 suppl 2:22-26.
39. Kirby, R.S. Coppinger, S.W.C. Gorcoran, M.O., Chapple, C.R., Flannagan, M. and Milroy, E.T.G. Prazosin in the treatment of prostatic obstruction. A Placebo controlled study. Brit. J. Urol. 1987; 60:136-142.
40. Jardin, A., Bensadoun, H., Delauche-cavallier, M.C. and Atali, P. Alfusozin for treatment of Benign prostatic hypertrophy. Lancet. 1991; 337:1457-1461.
41. Scott, M.A. and Abrams, P.H. Indoramin in the treatment of prostatic bladder outflow obstruction. Brit. J. Urol. 1991; 67:499-501.
42. Disilviero, F. Use of terazosin in the medical treatment of Benign prostatic byperplasia. Experience in Italy. Brit. J. Urol. 1992; 70 (suppl 1):22-26.
43. Chapple, C.R., Carter, P. and Christmas, T.J. et al. A three month double blind placebo controlled study of doxazosin as treatment for benign prostatic bladder outflow obstruction. Brit. J. Urol. 1994; 74:50-56.